Verve Therapeutics
Recent Finacing
Series B
Recent Raise
$94M
Verve Therapeutics develops one-time, liver-targeted in vivo adenine base-editing therapies delivered by lipid nanoparticles to edit PCSK9 and permanently lower LDL cholesterol, advancing IND-enabling studies toward clinical trials.
Highlights
Focus Areas
Biotechnology
Genetics
Life Science
Recent Investors
Financials
$215.5M
Total Raised
3
Funding rounds
15
Investors